# Cholangiocarcinoma and Biliary Tract Cancers

> Cholangiocarcinoma for NEET-PG Medicine, covering Klatskin tumour, PSC and liver fluke risk, CA 19-9 limits, and the workup for painless obstructive jaundice.

- Canonical URL: https://prepelephant.com/topics/neet-pg/medicine/cholangiocarcinoma-and-biliary-tract-cancers
- Exam / course: NEET-PG · Subject: Medicine
- Publisher: PrepElephant (https://prepelephant.com) — Prepared and reviewed by the PrepElephant Academic Review Team
- First published: 2026-10-14
- Last updated: 2026-10-14
- Reference basis: Harrison's Principles of Internal Medicine; Sleisenger and Fordtran's Gastrointestinal and Liver Disease; Bailey and Love's Short Practice of Surgery
- How to cite: "Cholangiocarcinoma and Biliary Tract Cancers", PrepElephant, https://prepelephant.com/topics/neet-pg/medicine/cholangiocarcinoma-and-biliary-tract-cancers

## Direct answer

Cholangiocarcinoma is an adenocarcinoma arising from the epithelium of the bile ducts, and it usually presents late with painless obstructive jaundice. Perihilar tumours, known as Klatskin tumours, are the commonest type. Primary sclerosing cholangitis and liver fluke infection are the key risk factors. Surgical resection, or transplantation in selected perihilar cases, is the only potentially curative option, so staging and biliary drainage come before any treatment decision.

## What you must remember

- **Three sites:** intrahepatic, perihilar (Klatskin) and distal cholangiocarcinoma, with perihilar tumours at the hepatic duct confluence forming the largest group.
- **Strongest risk factor:** primary sclerosing cholangitis, which is closely linked to ulcerative colitis, so new jaundice in such a patient needs cancer evaluation.
- **Parasitic risk:** Opisthorchis viverrini and Clonorchis sinensis infection are IARC Group 1 carcinogens, relevant to Southeast Asian and East Asian practice.
- **Classic picture:** painless obstructive jaundice, pruritus, pale stools and weight loss, with a palpable non-tender gallbladder (Courvoisier sign) favouring a distal or pancreatic cause.
- **Tumour marker:** CA 19-9 is commonly raised but non-specific, and it also rises in benign cholestasis, so it is interpreted after biliary drainage.
- **Other biliary cancers:** gallbladder carcinoma is linked to gallstones and chronic typhoid carriage, while ampullary carcinoma often presents earlier because it blocks the duct at the papilla.
- **Bismuth-Corlette classification:** it grades perihilar tumours from type I to type IV by involvement of the confluence and hepatic ducts, guiding the extent of resection.

## A work-up from jaundice to resectability

A 62-year-old man with ulcerative colitis has three weeks of painless jaundice and itching. Ultrasound shows dilated intrahepatic ducts with no visible stone.

1. **Confirm the level:** CT and MRCP show where the duct is blocked and whether the obstruction is hilar, mid-duct or distal.
2. **Map the ducts:** MRCP or ERCP defines the Bismuth-Corlette type, which decides whether a curative resection is possible.
3. **Obtain tissue endoscopically:** Brushings or biopsies taken during ERCP are preferred, because percutaneous needle sampling risks seeding the needle tract.
4. **Drain before surgery:** Biliary stenting relieves jaundice and prevents cholangitis, especially when bilirubin is high or the future liver remnant is small.
5. **Stage the disease:** CT of the chest and abdomen looks for metastasis, and portal vein embolisation may enlarge the future liver remnant before a major right-sided resection.
6. **Choose the treatment:** Resectable disease goes to surgery, while unresectable disease is treated with palliative chemotherapy, such as gemcitabine with cisplatin (increasingly with durvalumab), alongside stenting.

## Where the exam tries to catch you

Biliary cancer questions usually test the marker, the biopsy route and the risk factor.

- **Trap:** Treating CA 19-9 as diagnostic. — **Correct:** It is non-specific and rises with any obstruction, so imaging and tissue are needed to confirm the diagnosis.
- **Trap:** Attributing all cases to PSC. — **Correct:** PSC drives many Western cases, while liver fluke infection is the major cause in Southeast Asia, and both are expected in viva answers.
- **Trap:** Doing a percutaneous needle biopsy of a resectable hilar tumour. — **Correct:** Endoscopic sampling is preferred, because needle tract seeding can compromise curative surgery.

The answer usually turns on resectability, so read every stem with that question in mind.

## Frequently asked questions

### Which risk factor is most strongly associated with cholangiocarcinoma?

Primary sclerosing cholangitis is the most strongly associated risk factor for cholangiocarcinoma in Western series, and it is closely linked to ulcerative colitis. Patients with PSC who develop new jaundice or a dominant stricture need prompt evaluation for malignancy.

### What is the role of CA 19-9 in diagnosing cholangiocarcinoma?

CA 19-9 is a useful but non-specific tumour marker in cholangiocarcinoma, and it is often raised in the disease. It is also raised in benign cholestasis, so it is measured after biliary drainage and never used alone to make the diagnosis.

### Why is endoscopic sampling preferred over percutaneous biopsy for resectable perihilar tumours?

Percutaneous needle sampling carries a risk of tumour seeding along the needle tract, which can compromise later surgery. Endoscopic brushing or biopsy during ERCP is therefore preferred when the perihilar tumour may be resectable.

### What does the Bismuth-Corlette classification tell the surgeon about a perihilar tumour?

The Bismuth-Corlette classification grades how far a perihilar cholangiocarcinoma extends into the hepatic duct confluence and the right or left hepatic ducts, using types I to IV. It guides the choice between limited and extended resection, so it forms part of preoperative staging.

### Which palliative chemotherapy combination is standard for unresectable biliary tract cancer?

Gemcitabine with cisplatin is the backbone palliative chemotherapy for unresectable biliary tract cancer, and current guidelines increasingly add durvalumab to it. Biliary stenting is still needed to relieve jaundice and prevent cholangitis, whatever systemic treatment is chosen.